proteonomix

About:

Proteonomix develops therapies using human stem cells and their derivatives to treat diabetes and cardiac diseases.

Description:

Our Technologies were developed over years of research and development at leading US medical universities. Several technologies are entering the commercialization phase and others are ready to proceed through the FDA phased human trials process.

Total Funding Amount:

$3.8M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Hawthorne, New Jersey, United States

Founded Date:

1995-01-01

Contact Email:

info(AT)proteonomix.com

Founders:

Michael Cohen

Number of Employees:

1-10

Last Funding Date:

2012-03-21

IPO Status:

Private

Industries: